ImpediMed Limited (ASX:IPD): SOZO Expansion, FY26 Performance and FDA Clearance in Focus

Aditi Sarkar

06 October 2026 03:48 PM AEDT

ImpediMed Limited (ASX:IPD): SOZO Expansion, FY26 Performance and FDA Clearance in Focus

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

ImpediMed Limited (ASX:IPD) reported Q4 FY26 Revenue of A$3.6 million, up 3% from the preceding quarter, while Annual Recurring Revenue reached A$14.4 million.
The company’s SOZO platform received US FDA clearance in August 2026 for assessing patients at risk of sarcopenia.
ImpediMed ended Q4 FY26 with A$15.3 million in cash after completing capital-raising activities during the financial year.
At the time of writing this article, ImpediMed Limited (ASX:IPD) was trading at AUD 0.007, up 30.00% during today’s trading session.

At the time of writing this article, ImpediMed Limited (ASX:IPD) was trading at AUD 0.007, up 30.00% during today’s trading session. ImpediMed is a medical technology company focused on bioimpedance spectroscopy-based systems used to assess and monitor fluid status and body composition. Its commercial activities are centred on the SOZO Digital Health Platform, with applications across cancer survivorship, lymphoedema assessment, body composition and heart health. Recent developments have included FY26 commercial progress, expanded US reimbursement coverage and regulatory clearance for an additional SOZO clinical application.

Company Business

ImpediMed develops and commercialises medical technology designed to provide clinicians with measurements relating to fluid status and tissue composition. The SOZO Digital Health Platform uses bioimpedance spectroscopy technology and provides rapid measurements that can support clinical assessment and patient monitoring.

The system is used across areas including breast cancer-related lymphoedema, body composition and fluid monitoring. The United States remains an important commercial market for the company, where ImpediMed has continued to expand SOZO installations and reimbursement coverage.

During FY26, the company also continued developing broader applications for SOZO across cancer survivorship, heart health and weight management. At the end of the first half of FY26, around 600 SOZO devices were deployed in the US, while the company reported a pipeline of approximately 700 potential units representing more than US$35 million in potential total contract value.

Recent Development

In August 2026, ImpediMed received US Food and Drug Administration 510(k) clearance for the use of SOZO in sarcopenia risk assessment. The expanded indication allows clinicians to use the platform to assess patients who may be at risk of low muscle mass or muscle loss.

The company indicated that the capability would be introduced through SOZO software version 6.3. The clearance broadens the clinical applications available through the SOZO platform and follows ImpediMed’s efforts to expand beyond lymphoedema monitoring into wider cancer survivorship and body composition applications.

Commercial progress was also reported during FY26. In the March quarter, ImpediMed generated A$3.5 million in revenue and sold 36 SOZO units, including 30 in the US. Breast cancer-related lymphoedema reimbursement coverage increased to approximately 328 million covered US lives, representing 94.3% national coverage at that point.

Financial Performance and Sector Context

ImpediMed reported revenue of A$7.5 million for the first half of FY26, an increase of 25% compared with the prior corresponding period. Annual Recurring Revenue was A$14.4 million, up 15%, while SOZO Core Business Total Contract Value reached A$8.7 million, increasing 9%.

Cash receipts were A$7.2 million and net operating cash outflows were A$8.5 million during the period. For Q4 FY26, revenue reached A$3.6 million, representing a 3% increase from Q3 FY26. Annual Recurring Revenue remained A$14.4 million and SOZO Core Business Total Contract Value was A$5.4 million.

The company recorded A$4.3 million in quarterly cash receipts, while net operating cash outflows were A$4.9 million. Cash at quarter-end stood at A$15.3 million.

Across the medical technology sector, commercialisation can depend on regulatory clearances, reimbursement arrangements and adoption by healthcare providers. For ImpediMed, reimbursement for breast cancer-related lymphoedema has remained an important Factor supporting access to SOZO testing in the US. The company reported coverage reaching about 95% of the US population by the end of Q4 FY26.

Risks to Consider

ImpediMed remains exposed to risks associated with healthcare technology commercialisation, including the pace of hospital adoption, reimbursement changes, regulatory requirements and execution of new clinical applications.

The business also continues to record operating cash outflows, making expenditure management and revenue conversion relevant financial considerations. Capital requirements are another factor to monitor, particularly given the company’s fundraising activity during FY26.

What to Watch Next

Future developments include the commercial rollout of the sarcopenia assessment capability following FDA clearance, progress in SOZO installations and contract activity across the US healthcare market.

Investors may also monitor Annual Recurring Revenue, quarterly cash receipts, operating cash expenditure and the pace at which newer applications in heart health, body composition and cancer survivorship contribute to commercial activity. Updates on reimbursement coverage and healthcare-provider adoption will remain relevant to the company’s US strategy.

Key Insights

ImpediMed entered FY27 with SOZO established across multiple clinical applications and with an expanded regulatory pathway following FDA clearance for sarcopenia risk assessment. FY26 updates showed revenue growth during the first half, continued recurring revenue generation and further progress in US reimbursement coverage.

At the same time, operating cash outflows and the company’s capital requirements remain factors to monitor. Future updates are expected to provide further information on SOZO adoption, new clinical applications, recurring revenue and cash expenditure.

FAQs

Q:What is ImpediMed Limited’s main business?

A:ImpediMed develops medical technology based on bioimpedance spectroscopy, with its primary commercial platform being the SOZO Digital Health Platform.

Q:What was ImpediMed’s Q4 FY26 revenue?

A:ImpediMed reported Q4 FY26 revenue of A$3.6 million, up 3% from Q3 FY26.

Q:What regulatory clearance did ImpediMed receive in August 2026?

A:The company received US FDA clearance allowing SOZO to be used for sarcopenia risk assessment.

Q:What was ImpediMed’s Annual Recurring Revenue at the end of Q4 FY26?

A:Annual Recurring Revenue was A$14.4 million.

Q:What developments may be monitored next for ImpediMed?

A:Key areas include SOZO installations, recurring revenue, cash expenditure, reimbursement coverage and commercial progress across cancer survivorship, heart health and body composition applications.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.